Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Changchun BCHT Biotechnology Co's Debt-to-EBITDA or its related term are showing as below:
SHSE:688276'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.62 Med: 0.28 Max: 0.86
Current: -1.62
During the past 8 years, the highest Debt-to-EBITDA Ratio of Changchun BCHT Biotechnology Co was 0.86. The lowest was -1.62. And the median was 0.28.
SHSE:688276's Debt-to-EBITDA is ranked worse than 100% of 678
companies
in the Drug Manufacturers industry
Industry Median: 1.64
vs SHSE:688276: -1.62
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Changchun BCHT Biotechnology Co Debt-to-EBITDA Related Terms
Changchun BCHT Biotechnology Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Changchun BCHT Biotechnology Co Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Changchun BCHT Biotechnology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Changchun BCHT Biotechnology Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Changchun BCHT Biotechnology Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Changchun BCHT Biotechnology Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Changchun BCHT Biotechnology Co (SHSE:688276) has a Debt-to-EBITDA of -3.35 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Changchun BCHT Biotechnology Co. According to the industry distribution chart, Changchun BCHT Biotechnology Co ranks #999999 out of 678 companies in the Drug Manufacturers industry.
Is Changchun BCHT Biotechnology Co's Debt-to-EBITDA too high?
Changchun BCHT Biotechnology Co's current Debt-to-EBITDA is -3.35. Based on the distribution chart, Changchun BCHT Biotechnology Co ranks #999999 out of 678 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Changchun BCHT Biotechnology Co has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Changchun BCHT Biotechnology Co's Debt-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Changchun BCHT Biotechnology Co ranks #999999 out of 678 companies for Debt-to-EBITDA. This places Changchun BCHT Biotechnology Co in the lower half of its industry. The industry median Debt-to-EBITDA is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.64, based on 678 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Changchun BCHT Biotechnology Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Changchun BCHT Biotechnology Co's current Debt-to-EBITDA is -3.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Changchun BCHT Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Changchun BCHT Biotechnology Co (SHSE:688276) is currently considered Fairly Valued. The stock's GF Value™ is ¥16.39, compared to a current price of ¥15.36 — trading 6.3% below its estimated fair value. The current Debt-to-EBITDA is -3.35. Changchun BCHT Biotechnology Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Changchun BCHT Biotechnology Co (SHSE:688276), the current Debt-to-EBITDA is -3.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Changchun BCHT Biotechnology Co (SHSE:688276) Overvalued in 2026?
Based on GuruFocus' analysis, Changchun BCHT Biotechnology Co stock appears to be undervalued.
The current stock price of ¥15.36 is trading 6.3% below its estimated GF Value™ of ¥16.39.
GuruFocus considers Changchun BCHT Biotechnology Co to be Fairly Valued.
Key valuation signals for SHSE:688276:
Debt-to-EBITDA: -3.35
GF Value™: ¥16.39 vs. price of ¥15.36 (6.3% below fair value)
No single metric tells the full story. See the SHSE:688276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
70GF Score
Get the complete analysis for SHSE:688276
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688276 has been successfully added to your 
